Hycells New Product | Anti-Payload-DXD Antibody
Release Date:
2024-04-12 13:58
Anti-Payload-DXD Antibody
Antibody–drug conjugates (ADCs) are a class of promising biologic therapeutics designed to selectively deliver highly cytotoxic payloads to tumor cells while sparing normal tissues. They can be regarded as prodrugs: they remain stable in the bloodstream, minimizing drug release during circulation, and are efficiently converted into active drugs at the tumor site. To design the optimal tripartite combination of monoclonal antibody (mAb), linker, and cytotoxic payload, it is essential to monitor and understand the pharmacokinetic and pharmacodynamic properties of these three components in both the systemic circulation and the tumor microenvironment. In particular, the linker plays a critical role in determining the potency and safety profile of ADCs; therefore, in vivo monitoring of its behavior is crucial. Drug-Connector Stability “It is crucial for selecting the appropriate type of connector, which is achieved by determining the pharmacokinetics ( pharmacokinetics, PK ) is implemented through parameters.
The PK properties of the ADC are determined by assessing the following three entities:
(1) Conjugates (antibodies conjugated to at least one drug);
(2) Total antibody (antibody not conjugated with a drug);
(3) Free drug and its metabolites as physical entities. The focus is on the key analytical methods (ELISA, TFC-MS/MS, and HRMS) used to evaluate the PK parameters of these three entities, thereby enabling the assessment of drug–linker stability in ADCs.
Topoisomerase I inhibitors represent the most recently FDA-approved class of antibody–drug conjugate payloads. Topoisomerases are located in the cell nucleus and function to regulate and repair DNA supercoiling and entanglement that occur during DNA unwinding, transcriptional elongation, and DNA replication. DXD is an inhibitor of DNA topoisomerase I; topoisomerase inhibitors specifically bind to the interface of the DNA–topoisomerase complex, thereby inhibiting the topoisomerase-mediated repair mechanism, inducing DNA damage, and ultimately triggering apoptosis. The next-generation DXD–ADC conjugates employ DXD as the cytotoxic payload; due to its short plasma half-life, it helps minimize toxic side effects while exhibiting robust cell-membrane permeability and a bystander effect that enables it to kill neighboring tumor cells, further contributing to its shortened half-life.
DXD – Next-Generation ADC Payload
ADC-Pharmacokinetics (PK)
The pharmacokinetic profile of ADCs shares similarities with that of conventional antibody drugs, yet it is also influenced by the properties of the conjugated payload. The incorporation of a small-molecule drug into the ADC structure can increase its heterogeneity. When evaluating the pharmacokinetics of ADCs, researchers often analyze multiple analytes, including bound antibody, total antibody, bound effector molecule, free small-molecule cytotoxin, and their analogs.
The impact of ADC drugs on antibody concentrations in the body
The conjugation of drugs to antibodies can influence the antibody’s in vivo distribution, metabolism, and clearance rate, thereby affecting both the therapeutic efficacy and safety of the drug. Studies have shown that conjugation with small-molecule toxins increases the clearance rate of antibodies, and that the higher the drug–antibody ratio (DAR) in an ADC, the faster the ADC is cleared from the body. This indicates that drug conjugation accelerates antibody clearance, and a high DAR may further enhance this effect; such a mechanism is one of the key features of ADCs in cancer therapy.
Clearance pathways for reduced ADC drug concentrations
1. Degradation of the antibody moiety via enzymatic cleavage and other mechanisms: The antibody component of ADC drugs may be metabolically degraded by enzymes in the body, leading to a reduction in the overall concentration of the ADC.
2. Complete dissociation of the cytotoxic payload from the antibody (i.e., DAR = 0): This means the cytotoxic molecule has detached from the antibody and lost its ability to bind to it.
ADC Drug Degradation Pathways
Evaluation of the in vivo loss rate of ADC drugs
The drug loss rate refers to the extent of loss of the cytotoxic payload in antibody–drug conjugates (ADCs). In ADCs, the cytotoxic payload is typically delivered in a targeted manner through covalent conjugation to the antibody. Drug loss can reduce the targeting specificity and therapeutic efficacy of the agent and may even lead to adverse reactions. Therefore, assessing the in vivo drug loss rate is a critical step in the research and development of preclinical ADCs, as well as in evaluating their safety and efficacy.
The substantial discrepancy between antibody PK and total antibody PK indicates significant variability in the rate of drug loss or degradation within the body. The difference in the rate of change of antibody concentration and the clearance rate of the ADC drug indirectly reflects the stability of the ADC in the bloodstream, as it influences the duration of drug residence in the body and its therapeutic efficacy.
The clearance rate of ADC drugs is often higher than that of the total antibody concentration. Both drug degradation and the intrinsic clearance of the ADC itself contribute to the decline in intracellular drug concentrations, whereas the total antibody concentration is influenced solely by the clearance rates of the ADC and the unbound antibody. If the total antibody declines more rapidly while the ADC drug clearance rate remains relatively low, this may indicate a slower drug release from the ADC in vivo. Possible mechanisms include overly strong binding between the drug and the antibody or impediments in the drug-release mechanism. Total antibody and conjugated antibody levels are typically quantified using enzyme-linked immunosorbent assay (ELISA), whereas free and bound drug as well as metabolic degradation products are usually analyzed by liquid chromatography–mass spectrometry (LC-MS).
To support the pharmacokinetic analysis of DXD-ADC, Hycells Bio has launched the DXD Monoclonal Antibody, a product that Characterized by high specificity, high stability, and high sensitivity , antibodies capable of effectively determining the stability and release efficiency of DXD can be used for Plasma/serum pharmacokinetic analysis of ADC drugs, determination of drug-binding affinity, DAR value analysis, and evaluation of the therapeutic efficacy of ADC drugs. To accelerate the development of DXD-ADC drugs and provide a basis for their preclinical application and dose optimization.
Advantages of DXD Antibody Products
★ High purity: Verified by SDS-PAGE, with a purity greater than 90%;
DXD antibody on SDS-PAGE under reducing (R) conditions. The protein purity is greater than 90%.
★ High affinity: can bind DXD with high affinity;
Binding Activity of ADC-1(DXD) with Anti-DXD Antibody: Assessed by its binding capacity in a functional ELISA. Immobilized ADC-1(DXD) at 1 μg/mL binds the anti-DXD antibody, with an EC50 of 2.298–10 ng/mL.
★ DXD monoclonal antibody PK application assay demonstration:
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board